+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pulsed-dye laser versus intralesional Candida albicans antigen injection in treatment of genital warts

Pulsed-dye laser versus intralesional Candida albicans antigen injection in treatment of genital warts

Acta Dermatovenerologica Alpina Pannonica et Adriatica 28(1): 21-26

Genital warts are a troublesome therapeutic issue. Pulsed-dye laser (PDL) is a non-ablative therapeutic tool for viral warts. Intralesional Candida albicans (C. albicans) immunotherapy has yielded promising results in treatment of various types of warts. We aimed to evaluate the effectiveness of PDL versus C. albicans immunotherapy for treatment of genital warts. Forty adult patients with genital warts were divided into two equal groups; the first was treated using PDL and the second using intralesional C. albicans antigen injection. Treatments were performed at 3-week intervals until complete lesion resolution or for a maximum of three sessions. PDL yielded higher complete clearance rates (95%) than C. albicans antigen (50%; p = 0.001), which in turn had the advantage of treating distant and internal genital warts. Apart from pain during the session in PDL, both modalities were well tolerated with no recurrence in cured patients during the 16-week follow-up period. PDL and C. albicans antigen injection are safe and effective treatment alternatives for genital warts. PDL yielded better frequencies of clearance, but C. albicans antigen has additional advantages, including a single injection site and treating distant and internal mucosal uninjected warts, which are usually difficult to treat.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 066616030

Download citation: RISBibTeXText

PMID: 30901065

Related references

Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Archives of Dermatology 146(12): 1431-1433, 2010

Candida albicans intralesional injection immunotherapy of warts. Cutis 70(3): 185-192, 2002

Immunotherapy with intralesional Candida albicans antigen in resistant or recurrent warts: a study. Indian Journal of Dermatology 58(5): 360-365, 2013

Significance of interferon gamma in the prediction of successful therapy of common warts by intralesional injection of Candida antigen. International Journal of Dermatology 56(10): 1003-1009, 2017

Preliminary study of intralesional bleomycin injection for the treatment of genital warts. Annals of Dermatology 27(2): 239-241, 2015

Pulsed dye laser and intralesional bleomycin for the treatment of recalcitrant cutaneous warts. Lasers in Surgery and Medicine 46(2): 112-116, 2014

Successful treatment of flat warts using intralesional Candida antigen. Archives of Dermatology 139(4): 541-542, 2003

Pulsed dye laser and intralesional bleomycin for treatment of resistant viol hand warts. Lasers in Surgery and Medicine 30(2): 135-140, 2002

Comparative study of aminolevulic acid photodynamic therapy plus pulsed dye laser versus pulsed dye laser alone in treatment of viral warts. Photomedicine and Laser Surgery 23(2): 202-205, 2005

Intralesional Candida Antigen Immunotherapy for the Treatment of Recalcitrant and Multiple Warts in Children. Pediatric Dermatology 32(6): 797-801, 2015

A comparative study of pulsed dye laser versus long pulsed Nd:YAG laser treatment in recalcitrant viral warts. Journal of Dermatological Treatment 28(5): 411-416, 2017

Pulsed dye laser treatment of genital warts. Lasers in Surgery and Medicine 38(4): 273-276, 2006

Treatment of genital warts in males by pulsed dye laser. Journal of Cosmetic and Laser Therapy 8(2): 92-95, 2006

An Alarming Complication of Candida albicans Antigen Treatment of Recalcitrant Warts. Dermatitis 16(4): 216-217, 2005

An alarming complication of Candida albicans antigen treatment of recalcitrant warts. Dermatitis 16(4): 216; Author Reply 216-7, 2005